Arrowhead Pharmaceuticals, Inc. (ARWR)
| Market Cap | 9.75B |
| Revenue (ttm) | 1.09B |
| Net Income (ttm) | 202.27M |
| Shares Out | 140.03M |
| EPS (ttm) | 1.48 |
| PE Ratio | 49.89 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 934,913 |
| Open | 73.50 |
| Previous Close | 73.60 |
| Day's Range | 69.54 - 74.49 |
| 52-Week Range | 12.44 - 76.76 |
| Beta | 1.27 |
| Analysts | Strong Buy |
| Price Target | 83.40 (+19.83%) |
| Earnings Date | May 7, 2026 |
About ARWR
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene ... [Read more]
Financial Performance
In fiscal year 2025, Arrowhead Pharmaceuticals's revenue was $829.45 million, an increase of 23258.15% compared to the previous year's $3.55 million. Losses were -$1.63 million, -99.73% less than in 2024.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for ARWR stock is "Strong Buy." The 12-month stock price target is $83.4, which is an increase of 19.83% from the latest price.
News
Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (EMA CHM...
This Pharma Stock Is Up 460% Over the Past Year. What Could Be Key to Future Gains.
Arrowhead Pharmaceuticals stock could build on its rally in the third quarter, Morgan Stanley says.
Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Second Quarter Results
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 7, 2026, at 4:30 p.m. ET to discuss i...
Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology's 75th Annual Scientific Session and Expo
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced long-term efficacy and safety data from a two-year long open-label extension (OLE) study of ...
Arrowhead Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026
Multiple late-stage clinical readouts, including SHASTA-3/4 and first-in-class bispecific RNA data, are expected in Q3. Commercial focus is on high-risk populations, with innovation in delivery and dimer technology driving differentiation. Ex-US strategy adapts to pricing uncertainties, while platform expansion targets new tissues and CNS indications.
Arrowhead Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference
The company is prioritizing cardiometabolic and CNS programs, with major data readouts for plozasiran and ARO-MAPT expected in 2026. Waylivra's launch for FCS has exceeded expectations, and the pipeline includes innovative obesity, liver, and lipid therapies, with a focus on premium pricing and strategic market positioning.
Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: TD Cowen 46th Annual H...
Arrowhead Pharmaceuticals Earnings Call Transcript: Q1 2026
REDEMPLO received first approvals and launched in the U.S. with strong early uptake and positive payer feedback. Financials turned positive on $264M revenue, driven by licensing and milestones, and the balance sheet was significantly strengthened. Multiple late-stage readouts and launches are expected in 2026.
Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2026 first quarter ended December 31, 2025. The Company is ...
Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600
NEW YORK, Feb. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, S&P SmallCap 600: S&P MidCap 400 constituent Ciena Corp. (NYSE: CIEN) will...
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-DIMER-PA, the com...
Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 5, 2026, at 4:30 p.m. ET to disc...
Arrowhead Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference
The company highlighted strong financial resources and a broad RNAi pipeline, with Rudemplo already launched for FCS and label expansion studies underway. Key programs in cardiometabolic, obesity, and CNS are advancing, with multiple clinical milestones and commercial launches expected through 2028.
Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the pricing of its concurrent public offerings of (i) $625,000,000 aggregate principal amoun...
Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the Chinese National Medical Products Administration (NMPA) has approved REDEMPLO® (plo...
Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its intention to offer, subject to market and other conditions, $500 million aggregate princ...
Arrowhead Pharmaceuticals Transcript: Study Update
Interim phase I/II data show ARO-INHBE and ARO-ALK7 achieve deep target knockdown and significant reductions in visceral and liver fat, especially in obese diabetics when combined with tirzepatide. Both agents are well tolerated, and combination therapy offers additive benefits for a high-need population.
Zepbound Boost Gets a Lift From Arrowhead's Drug. The Question Is Whether Patients Will Pay.
Arrowhead's experimental therapy helped patients on Lilly's Zepbound lose more weight and visceral fat—but cost and convenience could limit demand.
Arrowhead Obesity Drugs Show Significant Fat Loss In Early Human Trials
Arrowhead, Inc. (NASDAQ: ARWR) on Tuesday shared interim results from two Phase 1/2a trials of ARO-INHBE and ARO-ALK7, the company's investigational RNA interference (RNAi) therapeutics for obesity.
Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from two Phase 1/2a clinical trials of ARO-INHBE and ARO-ALK7, the company's...
Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that Health Canada has issued a Notice of Compliance (NOC) authorizing REDEMPLO™ (plozasiran...
Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Obesity KOL Webinar – ...
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on December 12, 2025, th...
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-MAPT, the company...
Arrowhead Pharmaceuticals Transcript: Evercore ISI 8th Annual HealthCONx Conference
Major milestones include the launch of Redemplo for FCS, ongoing Phase 3 studies for expanded indications, and a robust cardiometabolic pipeline. Key 2026 events are expected, including pivotal trial readouts and early data from obesity and Alzheimer's programs.